Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
NCT00005987 · Masonic Cancer Center, University of Minnesota · PHASE2 · terminated · last registry update 2017-11-29 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn because treatment guidelines changed” | Open Targets' class: study design | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision